Today, the FDA approved Oxytrol for Women, a patch containing oxybutynin that treats overactive bladder, for over-the-counter sale to women ages 18 and older.
Today, the FDA approved Oxytrol for Women, a patch containing oxybutynin that treats overactive bladder, for over-the-counter sale to women ages 18 and older. Men still need a prescription for the drug.
Oxybutynin is an anticholinergic agent that treats overactive bladder by relaxing the bladder muscles and decreasing muscle spasms. This is the first time an anticholinergic agent has been approved for OTC sale.
The approval comes in spite of an FDA advisory committee’s November vote recommending against OTC availability. Concerns cited include patients’ ability to self-select, and the possibility of men using the product off-label.
Merck, the company that will manufacture Oxytrol for Women, did not seek approval for OTC use in men, because studies showed that men were not reliably able to determine whether the drug was the appropriate treatment for their urinary problems. In men, incorrect diagnosis of urinary issues could delay the detection of prostate cancer.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More